exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089318 RNA Name: hsa-miR-744-5p RNA Type: miRNA Chromosome: chr17 Starnd: + Coordinate: Start Site(bp): 12081909 End Site(bp): 12081930 External Links: hsa-miR-744-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AP5S1 chr20 3820524 3828838 + ARHGDIA chr17 81867721 81871378 - ARL8A chr1 202133404 202144743 - C8orf82 chr8 144525733 144529132 - CLSTN1 chr1 9728926 9823984 - CMIP chr16 81445170 81711762 + DLGAP4 chr20 36306336 36528637 + DNAJC30 chr7 73680918 73683453 - EEF1A2 chr20 63488014 63499185 - FAM219A chr9 34398184 34458570 - FAM83H chr8 143723933 143738234 - MGRN1 chr16 4616493 4690974 + MIDN chr19 1248553 1259140 + NFIX chr19 12995608 13098796 + NRARP chr9 137299631 137302271 - PHB2 chr12 6965327 6970753 - PRKCD chr3 53156009 53192717 + PRR12 chr19 49591182 49626439 + RAI14 chr5 34656328 34832612 + SCN1B chr19 35030470 35040449 + SH3GL1 chr19 4360370 4400547 - SMAD3 chr15 67063763 67195169 + SPRED2 chr2 65310851 65432637 - SYVN1 chr11 65121780 65134533 - WNT5A chr3 55465715 55490539 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002116.1 chr19 36008638 36014235 - AC008738.7 chr19 33207129 33207639 + AL356488.2 chr1 109100193 109100619 + GAS5 chr1 173858559 173868882 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.